AEON Biopharma annual r&d spending
2021
2022
2023
2024
2025
AEON Biopharma R&D Spending Growth & History (AEON)
AEON Biopharma's r&d spending was $4.1M for fiscal 2025.
View full AEON Biopharma company overviewAEON Biopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.1M | −$10.1M | −71.13% |
| 2024 | 2024-12-31 | $14.2M | $938,000 | +7.08% |
| 2023 | 2023-12-31 | $13.2M | −$21.5M | −61.90% |
| 2022 | 2022-12-31 | $34.8M | $9.0M | +35.08% |
| 2021 | 2021-12-31 | $25.7M | — | — |
AEON Biopharma quarterly r&d spending
Q3.22
Q1.23
Q2.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.9M | $1.9M | +176.13% |
| Q1 2026 | 2026-03-31 | $2.0M | $1.2M | +146.55% |
| Q4 2025 | 2025-12-31 | $1.6M | −$1.4M | −47.07% |
| Q3 2025 | 2025-09-30 | $597,000 | −$375,000 | −38.58% |
| Q2 2025 | 2025-06-30 | $1.1M | −$3.4M | −76.03% |
| Q1 2025 | 2025-03-31 | $825,000 | −$4.9M | −85.61% |
| Q4 2024 | 2024-12-31 | $3.0M | — | — |
| Q3 2024 | 2024-09-30 | $972,000 | −$5.4M | −84.78% |
| Q2 2024 | 2024-06-30 | $4.4M | — | — |
| Q1 2024 | 2024-03-31 | $5.7M | −$3.5M | −37.73% |
| Q3 2023 | 2023-09-30 | $6.4M | −$1.1M | −14.56% |
| Q2 2023 · Jul 21 | 2023-07-21 | $1.6M | — | — |
| Q2 2023 · Jun 30 | 2023-06-30 | $9.0M | — | — |
| Q1 2023 | 2023-03-31 | $9.2M | — | — |
| Q3 2022 | 2022-09-30 | $7.5M | — | — |
AEON Biopharma r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, AEON Biopharma's r&d spending decreased from $25.7M to $4.1M, a change of −$21.6M. The latest reported quarter, Q2 2026, shows $2.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AEON Biopharma source filings ↗